Function, structure and quality of striated muscles in the lower extremities in patients with late onset Pompe Disease - an MRI study

Michael Vaeggemose Corresp., 1, Rosa Andersen Mencagli 1, Julie Schjødtz Hansen 1, Bianca Dräger 2, Steffen Ringgaard 2, Peter Young 2, John Vissing 4, Henning Andersen 1

1 Department of Neurology, Aarhus University Hospital, Aarhus N, Denmark
2 Department of Sleep Medicine and Neuromuscular Disorders, University Hospital Muenster, Münster, Germany
3 MR Research Centre, Aarhus University, Aarhus N, Denmark
4 Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Corresponding Author: Michael Vaeggemose
Email address: mivaeg@clin.au.dk

Background: Pompe Disease (PD) is a rare inherited metabolic myopathy, caused by lysosomal- α-glucosidase (GAA) deficiency, which leads to glycogen accumulation within the lysosomes, resulting in cellular and tissue damage. Due to the emergence of a disease modifying treatment with recombinant GAA there has been a large increase in studies of late onset Pompe Disease (LOPD) during the last decade. Methods: The present study evaluates muscle quality in 10 patients with LOPD receiving treatment with enzyme replacement therapy and in 10 age and gender matched healthy controls applying T1-weighted DIXON MR imaging and isokinetic dynamometry. Muscle quality was determined by muscle strength in relation to muscle size (contractile cross-sectional area, CSA) and to muscle quality (fat fraction). A follow-up evaluation of the patients was performed after 8-12 months. Patient evaluations also included: six-minute walking test (6MWT), forced vital capacity, manual muscle testing and SF-36 questionnaire. Results: Fat fraction of knee flexors (0.15 vs 0.07, p < 0.05) and hip muscles (0.11 vs 0.07, p < 0.05) were higher in patients than controls. In patients, contractile CSA correlated with muscle strength (knee flexors: r=0.86, knee extensors: r=0.88, hip extensors: r=0.83, p< 0.05). No correlation was found between fat fraction and muscle strength. The fat fraction of thigh muscles did not correlate with scores from the clinical tests nor did it correlate with the 6MWT. During follow-up, the contractile CSA of the knee extensors increased by 2%. No other statistically significant change was observed. Quantitative MRI reflects muscle function in patients with LOPD, but larger long-term studies are needed to evaluate its utility in detecting changes over time.
Function, structure and quality of striated muscles in the lower extremities in patients with late onset Pompe Disease – an MRI study

M. Vaeggemose¹, R. A. Mencagli¹, J.S. Hansen¹, B. Dräger², S. Ringgaard³, P. Young², J. Vissing⁴, H. Andersen¹

1. Department of Neurology, Aarhus University Hospital, Aarhus, Denmark
2. Department of Sleep Medicine and Neuromuscular Disorders, University of Münster, Münster, Germany
3. MR Research Centre, Aarhus University, Aarhus, Denmark
4. Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark

Corresponding Author:
Michael Vaeggemose¹
Palle Juul-Jensens Blvd. 99, 8200, Aarhus, Denmark
Email address: mivaeg@clin.au.dk
ABSTRACT

Background
Pompe Disease (PD) is a rare inherited metabolic myopathy, caused by lysosomal- α-glucosidase (GAA) deficiency, which leads to glycogen accumulation within the lysosomes, resulting in cellular and tissue damage. Due to the emergence of a disease modifying treatment with recombinant GAA there has been a large increase in studies of late onset Pompe Disease (LOPD) during the last decade.

Methods
The present study evaluates muscle quality in 10 patients with LOPD receiving treatment with enzyme replacement therapy and in 10 age and gender matched healthy controls applying T₁-weighted DIXON MR imaging and isokinetic dynamometry. Muscle quality was determined by muscle strength in relation to muscle size (contractile cross-sectional area, CSA) and to muscle quality (fat fraction). A follow-up evaluation of the patients was performed after 8-12 months. Patient evaluations also included: six-minute walking test (6MWT), forced vital capacity, manual muscle testing and SF-36 questionnaire.

Results
Fat fraction of knee flexors (0.15 vs 0.07, p < 0.05) and hip muscles (0.11 vs 0.07, p < 0.05) were higher in patients than controls. In patients, contractile CSA correlated with muscle strength (knee flexors: r=0.86, knee extensors: r=0.88, hip extensors: r=0.83, p< 0.05). No correlation was found between fat fraction and muscle strength. The fat fraction of thigh muscles did not correlate with scores from the clinical tests nor did it correlate with the 6MWT. During follow-up, the contractile CSA of the knee extensors increased by 2%. No other statistically significant change was observed.

Quantitative MRI reflects muscle function in patients with LOPD, but larger long-term studies are needed to evaluate its utility in detecting changes over time.
1. Introduction

Pompe Disease (PD) is a rare inherited metabolic myopathy, caused by lysosomal-α-glucosidase (GAA) deficiency, which leads to glycogen accumulation within the lysosomes, resulting in cellular and tissue damage [1]. PD presents clinically in two forms, the infantile Pompe with no residual enzyme activity [2] [3], and the less severe late onset Pompe Disease (LOPD). LOPD may be symptomatic from young age to adulthood and is characterized by some residual activity of GAA. The skeletal muscles gradually degenerate with accumulating fat infiltration [4]. Skeletal muscle dysfunction results in muscle weakness, fatigue and respiratory insufficiency. With disease progression, patients may become wheelchair-bound and need ventilator support [3] [5], and have reduced life expectancy [6].

Due to the emergence of a disease modifying treatment with recombinant GAA there has been a large increase in studies of LOPD during the last decade, which have expanded our knowledge about LOPD as a broader phenotype of a multisystemic disease [7]. Treatment with recombinant GAA, also known as enzyme replacement therapy (ERT), has been available for LOPD since 2006, and new drugs are under development. Enzyme replacement therapy (ERT) has a well-established but moderate effect in most patients, however, the response to the treatment varies [8]. In a slowly progressing disease such as LOPD, monitoring the effect of a treatment is challenging, particularly as the treatment merely attenuates the disease progression rather than improving the functional capacity. The European Guidelines [9] recommend the following three endpoints for monitoring the disease: I. Functional tests; primarily the 6 minutes walking test (6MWT) and the four timed tests (walking 10 metres, climbing four steps, standing up from supine position and standing up from a chair). II. Forced vital capacity (FVC) in sitting and lying position and maximal inspiratory/expiratory pressure (MIP/MEP). III. Muscle strength assessed by manual muscle test (MRC).

However, the recommended tests are susceptible to variation in performance, due to patient dependence (lack of motivation and concentration, fatigue, pain, learning effects, and inherent variations in the measurements). This impedes detection of small changes in the patient’s performance, especially over short periods of time and in small patient populations. Thus, there is still the need for sensitive and reliable objective methods to monitor LOPD patients.
Magnetic resonance imaging (MRI) is a promising tool as it enables identification and quantification of fat replacement in skeletal muscles. In recent years, there has been a growing interest in the clinical use of MRI of skeletal muscles in neuromuscular disorders. Studies have reported close correlations between MRI findings and clinical tests although semi quantitative methods were primarily used. Interestingly, quantitative MRI has also been shown to enable detection of subclinical changes in fat fraction over time. However, results are difficult to compare as some MRI studies have not included quantitative techniques to determine strength of individual muscle groups, have only performed cross sectional studies or have only included a few muscle groups.

Therefore, the aims of this study were to evaluate the quality of a high number of muscles in patients with LOPD by determining the correlation between isokinetic muscle strength and the contractile cross-sectional area (CCSA). Furthermore, to evaluate whether changes in fat infiltration and the contractile cross sectional determined by MRI in the lower extremity corresponds to changes in disease severity during a shorter follow up period.

2. Materials and methods

2.1. Population

Between September 2015 and May 2017, all 11 Danish patients diagnosed with LOPD were invited to participate in the study. Eight accepted participation, one did not answer, and two declined participation due to the need for respiratory support during the MR scan. To increase the statistical power of the study, two patients were recruited from the Department of Sleep Medicine and Neuromuscular Disorders at Münster University Hospital, Germany, resulting in a total of 10 patients with a genetically confirmed diagnosis of LOPD (Figure 1). All patients were examined at day 1 and again after 8 months, except 3 patients, who were diagnosed during the study period. They were examined after 12 months to experience a complete 8 months of drug administration for study comparison. Nine patients received alglucosidase alfa and 1 patient received avalglucosidase alfa (neoGAA).
For comparison, 10 healthy controls matched for age, sex, height and weight were recruited and examined. Controls were recruited through advertisement in a local newspaper, on an online webpage for healthy controls and through public posters.

Exclusion criteria were: Age < 18 years, contraindications to MRI (metal in the body, pacemaker, pregnancy, and claustrophobia), cancer and other serious medical conditions and abuse of alcohol. Healthy control subjects were only examined by isokinetic dynamometry and MRI. All participants gave informed signed consent and were examined at the Department of Neurology, Aarhus University Hospital, Denmark. The study was approved by the Danish National Committee On Health Research Ethics (application no. 49089) and by the Danish Data Protection Agency. The study was registered at ClinicalTrials.gov (identifier: NCT02708784).

2.2. MRI acquisition
MR scanning was performed at the MR Centre at Aarhus University Hospital using a 3-T Siemens Skyra Magnetom (Siemens AG, Erlangen, Germany). The scan protocol consisted of a T1-weighted, 3-point gradient echo DIXON sequence (400 slices of 3 mm thickness, 20% gap, TR 5.31 ms, TE 2.46 ms, flip angle 9°, FOV 500, in-plane resolution 1 x 1 mm) acquiring images in a total scan time of 40 minutes. Participants were lying in a feet-first supine position and MR images were recorded from the ankle (lateral malleolus) to the trochanter major with the use of a 36 channel peripheral angio coil (Siemens AG, Erlangen, Germany) and from the trochanter major to L1 with a 18 channel body matrix coil (Siemens AG, Erlangen, Germany).

2.3. MRI data analysis
MR images were analysed using Osirix (Version 6.5.2, Pixmeo SARL, Switzerland). Muscle segmentation was done manually by segmenting regions of interest (ROI) in the T1-weighted opposed-phase images, recorded with the Dixon sequence. The following 12 muscles were segmented at the non-dominant thigh: biceps femoris caput longum muscle, semimembranosus muscle, semitendinosus muscle, rectus femoris muscle, vastus medialis muscle, vastus lateralis muscle, vastus intermedius muscle, sartorius muscle, gluteus maximus muscle, adductor magnus...
muscle, adductor longus muscle and iliopsoas muscle. To determine the muscle and fat fractions
the ROIs were applied to the corresponding fat and water images calculated from the Dixon
sequence. Based on the signal intensity (SI) the muscle fat fraction was calculated as the signal
intensity from the fat image divided with the combined fat and water signal intensity from a given
ROI (\( \text{FF} = \frac{\text{SI}(\text{fat})}{\text{SI}(\text{fat}) + \text{SI}(\text{water})} \)).

The fat fraction of the knee flexors was calculated as the mean fat faction from the following
muscles: biceps femoris caput longum, semimembranosus and semitendinosus; the fat fraction
of the knee extensors was calculated including the muscles: sartorius, rectus femoris, vastus
lateralis, vastus intermedius and vastus medialis.

The contractile cross-sectional area (CSA) was determined as the cross-sectional muscle area
subtracted the fat infiltrated muscle area (\( \text{CSA} = \text{Area} \times [1 - \text{FF}] \)) similar to the method described
by Carlier et al [11]).

To reduce bias in segmentation of muscles close to ligaments five cross sections of each muscle
were segmented with respect to the centre slice between two bone fix points illustrated by figure
2. For the knee extensors, the knee flexors, the adductor magnus muscle and the adductor longus
muscle, the slices chosen corresponded to the middle five slices between the trochanter major
on the femur and the upper edge of the patella. The five slices analysed to evaluate the gluteus
maximus muscle and the iliopsoas muscle corresponded to the most proximal part of the femur
bone. The slices chosen correspond to the slice where the caput femoris first appears together
with the two nearby proximal and distal slices. Although, this results in segmentation of the most
distal part of the iliopsoas muscle, which is not representative for the whole muscle, this
segmentation was chosen as respiration and bowel artefacts was present in images of the m.
iliopsoas more proximally. The vastus intermedius and the vastus lateralis muscles are difficult to
discriminate and therefore the muscles were analysed together, as proposed by Barnouin et al.
[18]. The short head on the biceps femoris muscle was not analysed, as the muscle was not visible
in all subjects on the chosen slices. Due to respiratory difficulties patient 1 was supported with
cushions enabling only MRI images from the ankle to the upper knee.
2.4. Isokinetic muscle strength

Isokinetic muscle strength was assessed by dynamometry using a Biodex System 3 PRO dynamometer (Biodex Medical System, NY USA; software version 3.1) as described earlier [19]. The protocol included eight repetitions for each movement and standardized instructions before and during the tests. The maximal peak torque was used for further analysis together with the percentage of expected strength, calculated according to Harbo et al. In case of a coefficient of variation > 15%, the test was repeated. Maximal muscle strength was determined for the flexors and extensors of the ankle, knee, hip, elbow and wrist, together with shoulder abduction and adduction. Patient 1 was unable to perform hip flexion and extension, due to need of respiratory support in supine position. Patients 3, 6 and 9 were not able to perform all the tests due to muscle weakness and pain. Patient 3 could only perform hip flexion, shoulder abduction, elbow flexion and hand flexion and extension. Patient 6 was unable to perform hip flexion and extension. Patient 9 was unable to perform hip flexion, shoulder abduction and elbow flexion.

2.5. Clinical measurements

Muscle strength was determined by manual muscle testing by a trained neurologist (HA) and graded as follows (0 = full strength, 1 = 25% reduced strength, 2 = 50% reduced strength, 3 = 75% reduced strength and 4 = 100% reduced strength). Exercise capacity was assessed by the 6 minutes walking test (6MWT). Vital capacity was determined according to the European Respiratory Society Guidelines [20] using a spirometry system in both sitting and supine position. The highest measurement out of three consecutive tests, defined as % of expected forced vital capacity (FVC) in litres, was used in further analyses. Perceived quality of life was established according to the Danish version of the 36-Item Short Form (SF-36) questionnaire. Finally, the patients were ranked according to each of these clinical measurements, and a summed rank-score was obtained as a measure of the combined disease severity status based on the 10 participating LOPD subjects.
2.6. Statistical analysis

Muscle strength, fat fraction and contractile CSA in LOPD patients were compared to healthy controls by paired t-test and Wilcoxon signed rank test. Correlations between muscle strength and muscle quality and between total fat fraction and clinical tests were tested by Spearman’s correlation and linear regression both for patients and controls. Follow-up data were analysed using paired t-test. Statistical significance was determined with a p-value of 0.05 or less.

3. Results

Demographics of the ten patients with LOPD and ten healthy matched controls are shown in table 1. Furthermore, the clinical characteristics with gene mutations of the patient population are described in table 2.

3.1 Contractile cross-sectional area and fat fraction

Contractile CSA of the knee flexors, the knee extensors, the gluteus maximus muscle and the adductor magnus muscle was reduced in the patients compared to their healthy controls (table 3). However, no statistical difference was found for the iliopsoas muscle and the adductor longus muscle. In all muscles examined, patients had a higher fat fraction, apart from the knee extensors (table 3 and figure 3). In the lower limbs, patients had reduced strength of knee extensors, hip flexors and hip extensors. In the upper limb, strength was reduced for shoulder adductors and elbow flexors only (table 3).

3.1.1 Muscle quality

Close correlations were found between the contractile CSA and muscle strength of the knee extensors in both healthy controls and patients (table 4). In patients, the contractile CSA of the knee flexors and hip extensors and the fat fraction of the knee flexors also correlated with muscle strength.
No correlation was found between the total fat fraction and the summed rank-score determined from the clinical tests, nor between the total fat fraction and the 6MWT (table 4).

3.1.2 Longitudinal analysis

During the follow-up period no change was observed at any of the clinical tests (table 5). Contractile CSA of the knee extensors increased slightly. The other contractile CSA and the fat fractions remained stable (tables 6 and 7).

No correlation was found between the change in expected muscle strength and the change in the total fat fraction, neither between the relative changes in % of total expected muscle strength and total fat fraction or total CSA (figure 4).

4. Discussion

Fat fraction determined by MRI was higher in patients with LOPD as compared to healthy controls. The replacement of muscle by fat followed a selective pattern, with more involvement of the adductor magnus muscle, the muscles at the pelvic girdle and the hamstrings combined with selective sparing of the short head of the biceps femoris muscle. This finding is in line with previous studies [4] [21]. In patients with more advanced disease there was fat replacement in knee extensors also, however, there was selective sparing of the rectus femoris, sartorius and gracilis muscles. Although the fat fraction of the healthy controls was lower than the patients’, the controls had a surprisingly high fat fraction compared to earlier studies [22] [23] [24]. This could be due to inclusion of physically less active subjects as in earlier studies.

Contractile CSA of the knee extensors closely correlated with isokinetic strength both in patients and controls. In patients, close correlations were also found between the contractile CSA of the knee flexors and hip extensors when compared to muscle strength. However, no correlation was found for hip flexion, which may due to a smaller muscle size. The iliopsoas muscle was analyzed only very distally due to bowel and respiration artefacts, which may explain the lack of correlation between contractile CSA and muscle strength. Pichiecchio et al reported close correlations
between muscle volume and strength, however, they only used semiquantitative strength measurements [21]. Similar close correlations between strength and contractile CSA have also been described in other neuromuscular disorders supporting the sensitivity of the MRI method [23] [25].

In contrast to previous studies of patients with LOPD and other neuromuscular disorders [21] [23] [24] [16] [26] [27] [28] [15] [29], we did not find any correlation between fat fraction and muscle strength, with the exception of the knee flexors. In the studies by Figueorora-Bonaparte et al and Khan et al there was a very close relationship between motor function tests including muscle strength and fat fraction. The discrepancy with our study may be due to more severely affected patients and a larger study population compared to our study. Interestingly, our findings are similar to those of Bonaparte et al. [16] who also studied muscles in patients with LOPD applying quantitative muscle strength measurements and MRI, and only found strong correlations for knee flexors (r=0.70), while the correlation for knee extensors was weaker (r=0.63). In line with our findings they reported no correlation for the hip flexors whereas they did not report on the hip extensors.

Unexpectedly, in our healthy control group we found only strong correlations for the contractile CSA of the knee extensors and hip flexors. This may be explained by a low number of subjects included. In healthy subjects there is a great variation in strength to CSA ratio [30], and this may explain our findings considering the larger variability of isokinetic testing of the knee flexors and the hip flexors and extensors as compared to the knee extensors.

In our LOPD patients, the mean fat fraction did not correlate with the overall clinical status, defined from the sum-rank score of the rankings from the clinical tests (vital capacity, SF-36, manual muscle testing and 6MWT). This is not surprising since some studies show a close correlation between fat fraction and functional tests, such as the 6MWT and “time to climb up/go down 4 stairs” [23] [16] [31] [32] [15], while other studies did not find any correlation [33] [32]. Such inconsistent findings may be explained by the high clinical heterogeneity of patients with LOPD and similar diseases [34]. Some patients have substantial weakness, pain [35] and fatigue...
[36], whereas others are asymptomatic. Pain and fatigue may impair physical performance unrelated to the conditions of the muscles.

During the follow-up period the only statistically significant change observed was a 2% increase of CSA of the knee extensors. No statistically significant changes were observed for any of the clinical tests, the fat fractions or the remaining CSAs. This is in contrast to the study by Khan et al and Nunez-Peralta et al who found a 1.3% and 1.9% annual increase in the fat fraction in patients receiving ERT, respectively [15,29]. In the studies, however, isokinetic dynamometry was not performed which impedes comparison between the studies.

An increase in size of the knee extensors has previously been described in treatment-naive LOPD patients: In two earlier studies by Pichiecchio et al. [37] and Ravaglia et al. [33] the muscle mass increased after only 6 months of ERT, and more recently a similar increase has been observed in the Embassy study [38]. A possible explanation is that a patient who started on ERT also started to be more active. However, this is not the case of our population, where only 3 patients started ERT treatment in relation to study inclusion.

During the follow-up period the mean fat fraction of the muscles remained stable, which is as described in the Embassy study. However, there was a large variation in the relative changes in fat fraction during the follow-up. Similar variations in changes of fat fraction have also been observed in patients with LGMD21 [39]. In contrast, Carlier et al. [14] observed an increase in fat fraction in 23 treated and untreated LOPD patients after only one year, with more rapid muscle degeneration in patients not receiving ERT. Also, despite ERT, Pichiecchio et al. [37] and Ravaglia et al. [33] reported an increased fat fraction of thigh muscles over time by quantitative MRI.

Compared to these studies, our population was considerably younger (mean age: 36 years, compared to 49 [14], 61 [37] and 54 [33] years, respectively). As fat replacement is part of the physiological ageing of striated muscles, this may partly explain the conflicting findings on muscle degeneration.

A recent retrospective study by Lollert et al. [32] including 13 patients with LOPD (age 30 ± 17.4, range 6-13) determined changes over time in intramuscular fat in the psoas major muscle and the paraspinal muscles. After 39 months, the fat fraction had increased in the psoas major
muscle. However, subgroup analysis of 7 subjects, who were followed for a longer time, did not reveal any significant change in fat fraction, indicating the general challenge of receiving statistical power in evaluation of rare disorders. Interestingly, in a newly published study by Rehmann et al, use of diffusion tensor imaging in MRI disclose abnormalities in muscle groups with low fat fraction which remain undetected by more conventional MRI techniques [17].

Our findings indicate that the contractile CSA more closely relates to the muscle strength of the given muscle as compared to fat fraction, which is in agreement with Carlier et al. [11]. Muscle imaging is a valuable tool to evaluate disease status, as it reflects muscle degeneration in a quantitative and objective way. However, due to considerable variations, muscle imaging should be considered as a supplement to clinical tests and questionnaires.

There are a number of limitations in our study. First, MR image resolution was set to 1 x 1 mm in-plane, which sets the lower boundary for precision of the analysis and thereby the sensitivity to detect small changes. However, we did use DIXON over T1 weighed images, thereby, applying a more robust method to alleviate the B0 and B1 field inhomogeneities often present in 3T MR imaging. Second, the limited number of participants does not allow us to perform subgroup analysis, e.g. drug naïve versus treated patients, and patients with low versus high levels of physical activity. Furthermore, not all patients performed all muscles tests which further lower the number of subjects in some analyses. As mentioned, the number of participants is a limiting factor, leading to indication of trends rather than showing statistical differences. The expected difference can be indicated by evaluating results from studies with 41 LOPD (13 in follow up) [32] and 32 LOPD (22 ERT, 10 HyperCKemia) [40] differences measured from MRI segmented muscles.

Our study is also limited by a large variation in patient characteristics, including considerable differences in clinical severity and a large age span (19-62 years), which makes subgroup analysis challenging. Due to the low prevalence of LOPD more detailed studies with stratification will only be possible in multicentre studies with standardized MRI protocols, as proposed by Hollingsworth et al. [41]. This will furthermore strengthen the power of the statistical analysis and thereby providing a more precise view of muscle involvement in LOPD.
5. Conclusion

Contractile CSA closely correlates to muscle strength in patients with LOPD. The average fat ratio of the thigh and hip muscles did not correlate to the 6MWT or the sum rank-score from conventional clinical tests. During the follow-up period the contractile CSA of the knee extensors increased by 2%, whereas, fat fraction of the hip and thigh muscles as well as functional tests remained unchanged.
6. References

[1] R. Hirschhorn, A.J.J. Reuser, ., in: McGraw-Hill (Ed.), Metab. Mol. Bases Inherit. Dis., 8th ed., Scriver, C R Beaudet, A L Sly, WS Valle, D, NY, 2001: pp. 3389–3420.

[2] P.S. Kishnani, W.-L. Hwu, H. Mandel, M. Nicolin0, F. Yong, D. Corzo, A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease, J. Pediatr. 148 (2006) 671-676.e2. https://doi.org/10.1016/J.PEDS.2005.11.033.

[3] A.T. Van Der Ploeg, A.J.J. Reuser, Lysosomal Storage Disease 2 Pompe’s disease, Lancet. 372 (2008) 1342–1353. https://doi.org/10.1016/S0140-6736(08)61555-X.

[4] R.-Y. Carlier, P. Laforet, C. Wary, D. Mompoint, K. Laloui, N. Pellegrini, D. Annane, P.G. Carlier, D. Orlikowski, Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns., Neuromuscul. Disord. 21 (2011) 791–9. https://doi.org/10.1016/j.nmd.2011.06.748.

[5] M.L.C. Hagemans, L.P.F. Winkel, P.A. Van Doorn, W.J.C. Hop, M.C.B. Loonen, A.J.J. Reuser, A.T. Van der Ploeg, Clinical manifestations and natural course of late-onset Pompe’s disease in 54 Dutch patients, Brain. 128 (2005) 671–677.

[6] D. Güngör, J.M. de Vries, W.C.J. Hop, A.J.J. Reuser, P.A. van Doorn, A.T. van der Ploeg, M.L.C. Hagemans, Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy, Orphanet J. Rare Dis. 6 (2011) 34. https://doi.org/10.1186/1750-1172-6-34.

[7] J. Chan, A.K. Desai, Z.B. Kazi, K. Corey, S. Austin, L.D. Hobson-Webb, L.E. Case, H.N. Jones, P.S. Kishnani, The emerging phenotype of late-onset Pompe disease: A systematic literature review, Mol. Genet. Metab. 120 (2017) 163–172. https://doi.org/10.1016/j.ymgme.2016.12.004.

[8] A.T. van der Ploeg, M.E. Kruijshaar, A. Toscano, P. Laforêt, C. Angelini, R.H. Lachmann, S.I. Pascual Pascual, M. Roberts, K. Rössler, T. Stulnig, P.A. van Doorn, P.Y.K. Van den Bergh, J. Vissing, B. Schoser, B. Bembali, A. Broomfield, M. Boentert, C. Desnuelle, O. Findling, A. Hahn, J. Diaz-Manera, T. Hundsberger, C. Kornblum, F. Labarthé, P. Laforêt, K.E. Mengel, T. Mongini, W. Muller-Felber, G. Parenti, W.P. Pijnappel, N. Preisler, S. Sacconi, B. Talim, M. Tardieu, N.A.M.E. van der Beek, S. Wenninger, European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience, Eur. J. Neurol. 24 (2017) 768-e31. https://doi.org/10.1111/ene.13285.

[9] B. Schoser, P. Laforêt, M.E. Kruijshaar, A. Toscano, P.A. Van Doorn, A.T. Van Der Ploeg, 208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26–28 September 2014, Neuromuscul. Disord. 25 (2015) 674–678. https://doi.org/10.1016/j.nmd.2015.04.006.

[10] V. Kalai, D.G. Leung, D.B. Sneag, F. Del Grande, J.A. Carrino, Advanced MRI Techniques for Muscle Imaging, Semin Musculoskelet Radiol. 21 (2017) 459–469. https://doi.org/10.1055/s-0037-1604007.

[11] P.G. Carlier, B. Marty, O. Scheidegger, P. Loureiro de Sousa, P.-Y. Baudin, E. Snezhko, D. Vlodavets, Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials, J. Neuromuscul. Dis. 3 (2016) 1–28. https://doi.org/10.3233/JND-160145.
[12] J. Burakiewicz, C.D.J. Sinclair, D. Fischer, G.A. Walter, H.E. Kan, K.G. Hollingsworth, Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy, J. Neurol. 264 (2017) 2053–2067. https://doi.org/10.1007/s00415-017-8547-3.

[13] D. Fischer, U. Bonati, M.P. Wattjes, Recent developments in muscle imaging of neuromuscular disorders, Curr. Opin. Neurol. 29 (2016) 614–620. https://doi.org/10.1097/WCO.0000000000000364.

[14] P.G. Carlier, N. Azzabou, P.L. de Sousa, A. Hicks, J.-M. Boisserie, A. Amadon, R.-Y. Carlier, C. Wary, D. Orlikowski, P. Laforêt, Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients, J. Inherit. Metab. Dis. 38 (2015) 565–572. https://doi.org/10.1007/s10545-015-9825-9.

[15] A.A. Khan, T. Boggs, M. Bowling, S. Austin, M. Stefanescu, L. Case, P.S. Kishnani, Whole-body magnetic resonance imaging in late-onset Pompe disease: Clinical utility and correlation with functional measures, J. Inherit. Metab. Dis. (2019) 549–557. https://doi.org/10.1002/jimd.12190.

[16] S. Figueroa-Bonaparte, S. Segovia, J. Llauger, I. Belmonte, I. Pedrosa, A. Alejaldre, M. Mayos, G. Suárez-Cuartín, E. Gallardo, I. Illa, J. Díaz-Manera, S.P.S. Group, Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function, PLoS One. 11 (2016) e0163493. https://doi.org/10.1371/journal.pone.0163493.

[17] R. Rehmann, M. Froeling, M. Rohm, J. Forsting, R.A. Kley, T. Schmidt-Wilcke, N. Karabul, C.H. Meyer-Friëßem, J. Vollert, M. Tegenthoff, M. Vorgerd, L. Schlaffke, Diffusion tensor imaging reveals changes in non-fat infiltrated muscles in late onset Pompe disease, Muscle and Nerve. 62 (2020) 541–549. https://doi.org/10.1002/mus.27021.

[18] Y. Barnouin, G. Butler-Browne, T. Voit, D. Reversat, N. Azzabou, G. Leroux, A. Behin, J.S. McPhee, P.G. Carlier, J.-Y. Hogrel, Manual segmentation of individual muscles of the quadriceps femoris using MRI: a reappraisal., J. Magn. Reson. Imaging. 40 (2014) 239–47. https://doi.org/10.1002/jmri.24370.

[19] T. Harbo, J. Brincks, H. Andersen, Maximal isokinetic and isometric muscle strength of major muscle groups related to age, body mass, height, and sex in 178 healthy subjects, Eur. J. Appl. Physiol. 112 (2012) 267–275. https://doi.org/10.1007/s00421-011-1975-3.

[20] P.. Quanjer, G.J. Tammeling, J.E. Cotes, O.F. Pedersen, R. Peslin, J.-C. Yernault, Lung volumes and forced ventilatory flows, Eur. Respir. J. 6 (1993) 5 LP – 40.

[21] A. Pichiecchio, C. Uggetti, S. Ravaglia, M.G. Eggitto, M. Rossi, G. Sandrini, C. Danesino, Muscle MRI in adult-onset acid maltase deficiency., Neuromuscul. Disord. 14 (2004) 51–5. http://www.ncbi.nlm.nih.gov/pubmed/15416214.

[22] J.Y. Hogrel, Y. Barnouin, N. Azzabou, G. Butler-Browne, T. Voit, A. Moraux, G. Leroux, A. Behin, J.S. McPhee, P.G. Carlier, NMR imaging estimates of muscle volume and intramuscular fat infiltration in the thigh: variations with muscle, gender, and age, Age (Omaha). 37 (2015) 1–11. https://doi.org/10.1007/s11357-015-9798-5.

[23] J.M. Morrow, C.D.J. Sinclair, A. Fischmann, P.M. Machado, M.M. Reilly, T.A. Yousry, J.S. Thornton, M.G. Hanna, MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study., Lancet. Neurol. 15 (2016) 65–77. https://doi.org/10.1016/S1474-4422(15)00242-2.

[24] J.J. Horvath, S.L. Austin, L.E. Case, K.B. Greene, H.N. Jones, B.J. Soher, P.S. Kishnani, M.R. Bashir, Correlation Between Quantitative Whole-Body Muscle Magnetic Resonance Imaging and Clinical Parameters in Adults with Pompe Disease: A Cross-Sectional Study, J. Neurosci. 37 (2017) 10597–10607. https://doi.org/10.1523/JNEUROSCI.4701-17.2017.
Imaging And Clinical Muscle Weakness In Pompe Disease, Muscle Nerve. 51 (2015) 722–730. https://doi.org/10.1002/mus.24437.

B.H. Wokke, J.C. van den Bergen, M.J. Versluis, E.H. Niks, J. Milles, A.G. Webb, E.W. van Zwet, A. Aartsma-Rus, J.J. Verschuuren, H.E. Kan, Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy, Neuromuscul. Disord. 24 (2014) 409–416. https://doi.org/https://doi.org/10.1016/j.nmd.2014.01.015.

A. Alejaldre, J. Díaz-Manera, S. Ravaglia, E.C. Tibaldi, F. D’Amore, G. Morís, N. Muelas, J.J. Vilchez, A. García-Medina, M. Usón, F.A. Martínez García, I. Illa, A. Pichiecchio, Trunk muscle involvement in late-onset Pompe disease: Study of thirty patients, Neuromuscul. Disord. 22 (2012) S148–S154. https://doi.org/10.1016/j.nmd.2012.05.011.

K. Mul, S.C.C. Vincenten, N.C. Voermans, R.J.L.F. Lemmers, P.J. van der Vliet, S.M. van der Maarel, G.W. Padberg, C.G.C. Horlings, B.G.M. van Engelen, Adding quantitative muscle MRI to the FSHD clinical trial toolbox, Neurology. 89 (2017) 2057–2065. https://doi.org/10.1212/WNL.0000000000004647.

G. Andersen, J.R. Dahlqvist, C.R. Vissing, K. Heje, C. Thomsen, J. Vissing, MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients, J. Neurol. 264 (2017) 438–447. https://doi.org/10.1007/s00415-016-8361-3.

C. Nuñez-Peralta, J. Alonso-Pérez, J. Llauger, S. Segovia, P. Montesinos, I. Belmonte, I. Pedrosa, E. Montiel, A. Alonso-Jiménez, J. Sánchez-González, A. Martínez-Noguera, I. Illa, J. Díaz-Manera, Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles, J. Cachexia. Sarcopenia Muscle. (2020). https://doi.org/10.1002/jcsm.12555.

R.J. Maughan, J.S. Watson, J. Weir, Strength and cross-sectional area of human skeletal muscle., J. Physiol. 338 (1983) 37–49.

D. Fischer, P. Hafner, D. Rubino, M. Schmid, C. Neuhaus, H. Jung, O. Bieri, T. Haas, M. Gloor, A. Fischmann, U. Bonati, The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: A cross-sectional study, Neuromuscul. Disord. 26 (2016) 414–422. https://doi.org/http://dx.doi.org/10.1016/j.nmd.2016.04.009.

A. Lollert, C. Stihl, A.M. Hötker, E. Mengel, J. König, K. Laudemann, S. Göke, C. Düber, G. Staatz, Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy, PLoS One. 13 (2018) 1–15. https://doi.org/10.1371/journal.pone.0190784.

S. Ravaglia, A. Pichiecchio, M. Ponzo, C. Danesino, K. Saeidi Garaghani, G.U. Poloni, A. Toscano, A. Moglia, A. Carlucci, P. Bini, M. Ceroni, S. Bastianello, Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response., J. Inherit. Metab. Dis. 33 (2010) 737–45. https://doi.org/10.1007/s10545-010-9204-5.

L. Harlaar, J.Y. Hogrel, B. Periconi, M.E. Kruijshaar, D. Rizopoulos, N. Taouagh, A. Canal, E. Brusse, P.A. van Doorn, A.T. van der Ploeg, P. Laforêt, N.A.M.E. van der Beek, Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease, Neurology. 93 (2019) e1756–e1767. https://doi.org/10.1212/WNL.0000000000008441.
[35] D. Güngör, A.K. Schober, M.E. Kruijshaar, I. Plug, N. Karabul, M. Deschauer, P.A. van Doorn, A.T. van der Ploeg, B. Schoser, F. Hanisch, Pain in adult patients with Pompe disease, Mol. Genet. Metab. 109 (2013) 371–376. https://doi.org/10.1016/j.ymgme.2013.05.021.

[36] M.L.C. Hagemans, S.P.M. van Schie, A.C.J.W. Janssens, P.A. van Doorn, A.J.J. Reuser, A.T. van der Ploeg, Fatigue: an important feature of late-onset Pompe disease, J. Neurol. 254 (2007) 941–945. https://doi.org/10.1007/s00415-006-0434-2.

[37] A. Pichiecchio, G.U. Poloni, S. Ravaglia, M. Ponzio, G. Germani, D. Maranzana, a Costa, a Repetto, E. Tavazzi, C. Danesino, a Moglia, S. Bastianello, Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful?, Muscle Nerve. 40 (2009) 122–5. https://doi.org/10.1002/mus.21304.

[38] A. van der Ploeg, P.G. Carlier, R.-Y. Carlier, J.T. Kissen, B. Schoser, S. Wenninger, A. Pestronk, R.J. Barohn, M.M. Dimachkie, O. Goker-Alpan, T. Mozaffar, L.D.M. Pena, Z. Simmons, V. Straub, M. Guglieni, P. Young, M. Boentert, P.-Y. Baudin, S. Wens, R. Shafi, C. Bjartmar, B.L. Thurlberg, Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study., Mol. Genet. Metab. 119 (2016) 115–23. https://doi.org/10.1016/j.ymgme.2016.05.013.

[39] T.A. Willis, K.G. Hollingsworth, A. Coombs, M.L. Sveen, S. Andersen, T. Stojkovic, M. Eagle, A. Mayhew, P.L. de Sousa, L. Dewar, J.M. Morrow, C.D.J. Sinclair, J.S. Thornton, K. Bushby, H. Lochmüller, M.G. Hanna, J.Y. Hogrel, P.G. Carlier, J. Vissing, V. Straub, Quantitative Muscle MRI as an Assessment Tool for Monitoring Disease Progression in LGMD2I: A Multicentre Longitudinal Study, PLoS One. 8 (2013). https://doi.org/10.1371/journal.pone.0070993.

[40] S. Figueroa-Bonaparte, J. Llauger, S. Segovia, I. Belmonte, I. Pedrosa, E. Montiel, P. Montesinos, J. Sánchez-González, A. Alonso-Jiménez, E. Gallardo, I. Illa, M.A. Barba-Romero, J. Barcena, P. Carbonell, M.R. Carzorla, C. Creus, J. Coll-Cantí, M. Díaz, C. Dominguez, R. Fernández-Torrón, M.J. García-Antelo, J.M. Grau, A.L. De Munáin, F.A. Martínez-García, Y. Morgado, A. Moreno, G. Morís, M.A. Muñoz-Blanco, A. Nascimento, J.L. Parajua, A. Robledo-Strauss, Í. Rojas-Marcos, J.A. Salazar, M. Usón, J. Díaz-Manera, Quantitative muscle MRI to follow up late onset Pompe patients: A prospective study, Sci. Rep. 8 (2018) 1–11. https://doi.org/10.1038/s41598-018-29170-7.

[41] K.G. Hollingsworth, P.L. de Sousa, V. Straub, P.G. Carlier, Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1-2 October 2009, Paris, France., Neuromuscul. Disord. 22 Suppl 2 (2012) S54-67. https://doi.org/10.1016/j.nmd.2012.06.005.
Highlights

1. Contractile CSA of lower extremities muscle groups correlates to muscle strength.
2. The fat ratio of the thigh and hip muscles did not correlate to clinical tests.
3. At follow-up the contractile CSA of the knee extensors had increased by 2%.
4. Fat fraction of the other muscle groups and all functional tests remained unchanged.
Figure 1

Flow chart of late onset Pompe disease and healthy control subjects participating in the study.
Figure 2

Illustration of muscle segmentation in the opposed phase DIXON MR images of the muscles of hip flexor/extensor and knee flexors/extensors, corresponding to the following individual muscles:

*M. iliopsoas, M. gluteus maximus, M. rectus femoris, M. sartorius, M. vastus medialis, M. vastus intermedius, M. vastus lateralis, M. biceps femoris, M. semimembranosus, M. semitendinosus.* The images are shown at comparable slices of A) a healthy subject, B) segmentation of the healthy subject muscles’, and C) a late onset Pompe subject.
Figure 3

Dot plot illustrating the fat fraction of each muscle in patients (circles) and controls (triangles).
Figure 4

Linear regression analysis of muscle strength and contractile CSA of the knee flexors (a) and knee extensors (b) in patients with LOPD (circle) and controls (triangle).
Table 1 (on next page)

Subjects’ demographics

(Values are given in mean values and range).
**Table 1 - Subjects’ demographics**

|                  | **LOPD** | **Controls** |
|------------------|----------|--------------|
| Number of subjects | 10       | 10           |
| Female (%)       | 5 (50)   | 5 (50)       |
| Age (years)      | 36 (19-62) | 38 (21-62)  |
| Height (cm)      | 178 (161-193) | 174 (161-180) |
| Weight (kg)      | 72.4 (58-102) | 72.9 (59-92) |

(Values are given in mean values and range).
Table 2 (on next page)

Clinical characteristics of the late onset pompe disease patients

During the study period patient 1-9 received alglucosidase alfa. Patient 10 received avalglucosidase alfa (neoGAA). ERT: Enzyme replacement therapy
| Patient | Sex | Age | Year of diagnosis | Start on ERT | Aids | Gene mutation |
|---------|-----|-----|-------------------|--------------|------|---------------|
| 1       | M   | 62  | 2000              | 2007         | B-pap at night | GAA-mutation: c*-32-13T>A |
|         |     |     |                   |              | GAA-mutation: | c.1003G>A |
| 2       | F   | 43  | 2010              | 2011         | ÷               | GAA-mutation: c-32-13T>A |
|         |     |     |                   |              | GAA-mutation: | c.307T>G;pC103G |
| 3       | F   | 40  | 2015              | 2015         | ÷               | GAA-mutation: c.32-13T>G, Homozygous |
| 4       | M   | 42  | 2015              | 2015         | ÷               | GAA-mutation: c.32-13T>G |
|         |     |     |                   |              | GAA-mutation: | c.525 del, p. Glu176Argfs*45 |
| 5       | M   | 44  | 2010              | 2011         | ÷               | GAA-mutation: c.32-13T>A |
|         |     |     |                   |              | GAA-mutation: | c.2331+2T>G |
| 6       | F   | 30  | 2016              | 2016         | Wheel chair for longer distance | GAA-mutation: c-32-13T>G |
|         |     |     |                   |              | GAA-mutation: | c.525 del, p. Glu176Argfs*45 |
| 7       | F   | 25  | 2013              | 2014         | Wheel           | GAA-mutation: c-32- |
During the study period patient 1-9 received alglucosidase alfa. Patient 10 received avalglucosidase alfa (neoGAA).

ERT: Enzyme replacement therapy

13T>G
good news

M 19 2014 2015
good news

F 34 2003 2014
good news

M 22 1995 2006
good news

GAA-mutation: c.32-13T>G
good news

c.1548G>A
good news

c.1802C>T
good news

GAA-mutation: IVS1-13T>G
good news

GAA-mutation: 2.228A>G
good news
Table 3 (on next page)

Fat fraction, contractile CSA and muscle strength in patients and in healthy controls.

* p < 0.05, ** p < 0.01. Values are given as mean and standard deviation or median and range. The superscript indicates the number of missing data in the patients group in the given analysis, e.g. fat-fraction superscript 1 indicates one missing data. Statistically significant differences are presented in bold.
Table 3 - Fat fraction, contractile CSA and muscle strength in patients and in healthy controls.

|                  | Patients                        | Controls                      |
|------------------|---------------------------------|-------------------------------|
| Fat fraction     |                                 |                               |
| Knee-extensors   | 0.12 (0.03-0.49)                | 0.09 ± 0.02                   |
| M. sartorius     | 0.16 ± 0.06                     | 0.02                          |
| M. rectus femoris| 0.10 ± 0.05                     | 0.14 ± 0.03                   |
| M. vastus medialis | 0.11 (0.03-0.75)             | 0.03                          |
| M. vastus lateralis et intermedius | 0.11 (0.04-0.73) | 0.08 ± 0.03 |
| Knee-flexors     |                                 |                               |
| M. biceps femoris, caput longum | 0.15 (0.08-0.75)  | 0.02 ± 0.03                   |
| M. semimembranosus | 0.32 ± 0.26*                   | 0.03                          |
| M. semitendinosus | 0.18 (0.05-0.75)              | 0.12 ± 0.03                   |
| M. adductor magnus | 0.77*                         | 0.03                          |
| M. adductor longus | 0.37 ± 0.29*                 | 0.12 ± 0.03                   |
| M. gluteus maximus | 0.16 (0.02-0.75)            | 0.02                          |
| M. iliopsoas     | 0.75*                           | 0.11 ± 0.04                   |
|                  | 0.32 ± 0.24*                    | 0.04                          |
|                  | 0.11 (0.05-0.75)                | 0.11 ± 0.03                   |
|                  | 0.73*                           | 0.03                          |
|                  | 0.10 ± 0.03                     |                               |
|                  | 0.08 ± 0.03                     |                               |
|                  | 0.15 ± 0.02                     |                               |
|                  | 0.06                            |                               |
|                  | 0.07 ± 0.03                     |                               |
|                  | 0.03                            |                               |
| Contractile CSA (cm²) | Knee-extensors¹ | 45.53 ± 14.38* | 57.84 ± 15.51 |
|----------------------|----------------|----------------|---------------|
|                      | M. sartorius¹  | 2.81 ± 1.10    |               |
|                      | M. rectus femoris¹ | 7.15 ± 2.01  | 2.54 ± 0.67   |
|                      | M. vastus medialis¹ | 4.67 ± 2.66** | 6.02 ± 1.76 |
|                      | M. vastus lateralis et intermedius¹ | 30.79 ± 12.05* | 9.26 ± 2.81 |
| Knee-flexors¹        | 16.83 (2.34-20.70)* | 40.61 ± 9.41  |               |
|                      | M. biceps femoris, caput longum¹ | 6.56 (0.66-8.49)* | 18.49 ± 5.41 |
|                      | M. semimembranosus¹ | 2.19 ± 1.57*   | 7.66 ± 2.56   |
|                      | M. semitendinosus¹ | 5.54 ± 3.48    | 2.64 ± 2.17   |
|                      | M. adductor magnus¹ | 7.87 ± 6.83** | 7.03 ± 1.84   |
|                      | M. adductor longus¹ | 3.11 ± 1.98    | 20.72 ± 5.02  |
|                      | M. gluteus maximus¹ | 28.50 ± 14.76* | 5.02 ± 1.36 |
|                      | M. iliopsoas¹ | 5.98 ± 3.28    | 39.49 ± 8.43 |
|                      |               | 6.68 ± 1.27    |               |

| Muscle strength (Nm) | Knee-extensors¹ | 103.2 ± 52.3** | 153.4 ± 25.6 |
|----------------------|----------------|----------------|---------------|
|                      | Knee-flexors¹  | 46.0 ± 25.2    |               |
|                      | Hip extensor²  | 62.8 ± 42.3*   | 64.5 ± 12.6   |
|                      | Hip flexors⁴   | 77.0 ± 35.1**  | 139.8 ± 25.5  |
|                      | Foot flexors¹  | 52.4 ± 13.5    | 139.8 ± 25.5  |
|                      | Foot extensors¹| 20.3 ± 15.2    | 25.5          |
|                      | Shoulder abductor¹ | 37.8 ± 15.7  | 120.6 ± 29.7  |
|                      | Shoulder adductor¹ | 43.4 ± 23.1* |               |
|                      | Elbow flexors¹ | 33.6 ± 11.7*   | 62.0 ± 11.3   |
|                      | Elbow extensors¹ | 33.2 ± 11.5  | 11.3          |
|                      | Hand flexors¹  | 16.6 ± 7.1     | 23.4 ± 11.3   |
| Hand extensors | 8.8 ± 4.2 | 14.7 |
|               | 44.8 ± 12.9 | **62.1 ± 19.2** |
|               | **40.6 ± 14.2** | 14.2 |
|               | 35.8 ± 8.4 | 14.9 ± 4.1 |
|               | 9.6 ± 1.7 |

3  * p < 0.05, ** p < 0.01.
4  Values are given as mean and standard deviation or median and range.
5  The superscript indicates the number of missing data in the patients group in the given analysis, e.g. fat-fraction\(^1\) indicates one missing data. Statistically significant differences are presented in bold.
6  
7  
8  
9  
10 
11
Table 4 (on next page)

Correlations between muscle strength and the corresponding MRI findings from the muscles (contractile CSA and fatfraction) and between the fatfraction and the clinical tests (sum rank score and 6MWT).

p < 0.05, ** p < 0.01. Analysis was done by Spearman´s correlation. The superscript indicates the number of missing data in the patients group in the given analysis, e.g. knee flexors² indicates missing data from two patients.
**Table 4** - Correlations between muscle strength and the corresponding MRI findings from the muscles (contractile CSA and fat fraction) and between the fat fraction and the clinical tests (sum rank score and 6MWT).

|                      | Patients | Controls |
|----------------------|----------|----------|
| **Contractile CSA**  |          |          |
| Knee flexors         | \( r = 0.86^{**} \) | \( r = 0.31 \) |
| Knee extensors       | \( r = 0.88^{**} \) | \( r = 0.90^{**} \) |
| Hip extensor         | \( r = 0.83^{*} \)  | \( r = 0.38 \) |
| Hip flexor           | \( r = 0.29 \)     | \( r = 0.67^{**} \) |
| **Fat fraction**     |          |          |
| Knee flexors         | \( r = -0.83^{*} \) | \( r = -0.14 \) |
| Knee extensors       | \( r = -0.43 \)    | \( r = -0.25 \) |
| Hip extensor         | \( r = -0.68 \)    | \( r = 0.07 \) |
| Hip flexor           | \( r = -0.14 \)    | \( r = 0.24 \) |
| **Total fat fraction** | |          |
| Sum rank-score       | \( r = 0.38 \)     |          |
| 6MWT                 | \( r = -0.50 \)    |          |

\( p < 0.05, \quad ^{*} p < 0.01. \)

Analysis was done by Spearman’s correlation. The superscript indicates the number of missing data in the patients group in the given analysis, e.g. knee flexors\(^2\) indicates missing data from two patients.
Table 5 (on next page)

Clinical test at baseline and at follow-up.

MMT = Manual muscle testing. SF-36 = 36-item short form questionnaire. 6 minute walking test (6MWT) is measured in minutes.
1 **Table 5** - Clinical test at baseline and at follow-up.

|                                | Baseline            | Follow-up           |
|--------------------------------|---------------------|---------------------|
| 6MWT (m)                       | 506.6 ± 143.89      | 490.3 ± 164.38      |
| % of expected FVC              |                     |                     |
| sitting position               | 88 ± 28             | 87 ± 24             |
| lying position                 | 75 ± 33             | 75 ± 29             |
| MMT                            | 17.2 ± 12.28        | 15.2 ± 10.99        |
| SF-36                           | 532.98 ± 168.28     | 464.07 ± 175.37     |
| % of expected total strength   | 63 ± 13             | 63 ± 11             |

2 MMT = Manual muscle testing. SF-36 = 36-item short form questionnaire. 6 minute walking test (6MWT) is measured in minutes.
The contractile cross-sectional area (CSA) at baseline and at follow-up.

The mean difference is calculated as follow-up value minus baseline value. Contractile cross-sectional area (CSA) is measured in cm$^2$. Values are given in mean and SD; Data without normal distribution are also presented as median and range.
|                          | Baseline                  | Follow-up                  | Mean difference |
|--------------------------|---------------------------|---------------------------|-----------------|
|                          | Mean difference + SD      |                           |                 |
| Knee flexors             | 16.83 (2.34-20.70)        | 16.71 (2.38-21.27)        | 0.30 ± 1.69     |
|                          | (13.24 ± 7.71)            | (13.53±8.01)              |                 |
| Knee extensors           | 45.53±14.38               | 46.53 ± 14.54**           | 1.01 ± 0.87**   |
| M. iliopsoas             | 5.98 ± 3.28               | 5.40 ± 3.46               | -0.58 ± 0.86    |
| M. gluteus maximus       | 28.50 ± 14.76             | 27.96 ± 14.08             | -0.54 ± 1.76    |
| M. adductor              | 7.87 ± 6.83               | 7.39 ± 6.29               | -0.48 ± 0.78    |
| M. adductor longus       | 3.11 ± 1.98               | 2.99 ± 1.96               | -0.12 ± 0.41    |
| Sum of CSA               | 104.23 ± 43.45            | 103.83 ± 42.76            | -0.42 ± 2.78    |

**p < 0.01.

The mean difference is calculated as follow-up value minus baseline value. Contractile cross-sectional area (CSA) is measured in cm². Values are given in mean and SD; Data without normal distribution are also presented as median and range.
Table 7 (on next page)

The fat fraction of the late onset Pompe Disease patients at baseline and follow-up.

The mean difference is calculated as follow-up value minus baseline value. Values are given in mean and SD; where data were not normally distributed median and range is given first.
1 Table 7 - The fat fraction of the late onset Pompe Disease patients at baseline and follow-up.

| Fat fraction                | Baseline          | Follow-up         | Mean difference |
|-----------------------------|-------------------|-------------------|-----------------|
|                             | Mean difference   | + SD              |                 |
| Knee flexors                | 0.21 (0.06 - 0.75)| 0.18 (0.08 - 0.76)| 0.00 ± 0.02     |
|                             | (0.32 ± 0.27)     | (0.32 ± 0.28)     |                 |
| M. biceps longum            | 0.15 (0.08 - 0.76)| 0.14 (0.10 - 0.76)| 0.00 ± 0.02     |
|                             | (0.32 ± 0.28)     | (0.32 ± 0.29)     |                 |
| M. semimembranosus          | 0.32 ± 0.26       | 0.32 ± 0.26       | -0.00 ± 0.03    |
| M. semitendinosus           | 0.18 (0.05 - 0.77)| 0.19 (0.08 - 0.78)| 0.01 ± 0.03     |
|                             | (0.31 ± 0.27)     | (0.32 ± 0.28)     |                 |
| Knee extensors              | 0.12 (0.03 - 0.49)| 0.13 (0.07 - 0.50)| 0.00 ± 0.03     |
|                             | (0.15 ± 0.13)     | (0.16 ± 0.13)     |                 |
| M. vastus med               | 0.11 (0.03 - 0.75)| 0.13 (0.07 - 0.78)| 0.03 ± 0.07     |
|                             | (0.18 ± 0.22)     | 0.21 ± 0.23       |                 |
| M. vastus lateralis et      | 0.11 (0.04 - 0.73)| 0.10 (0.06 - 0.76)| 0.00 ± 0.02     |
| intermedius                 | (0.17 ± 0.21)     | 0.17 ± 0.22       |                 |
| M. sartorius                | 0.16 ± 0.06       | 0.15 ± 0.06       | -0.01 ± 0.02    |
| M. rectus femoris           | 0.10 ± 0.05       | 0.09 ± 0.04       | -0.01 ± 0.03    |
| M. iliopsoas                | 0.11 (0.05 - 0.73)| 0.08 (0.05 - 0.69)| -0.02 ± 0.03    |
|                             | (0.17 ± 0.21)     | (0.15 ± 0.20)     |                 |
| M. gluteus maximus          | 0.32 ± 0.24       | 0.33 ± 0.24       | 0.00 ± 0.03     |
| M. adductor magnus          | 0.37 ± 0.29       | 0.38 ± 0.30       | 0.01 ± 0.03     |
| M. adductor longus          | 0.16 (0.02 - 0.75)| 0.15 (0.06 - 0.73)| -0.00 ± 0.04    |
|                             | (0.23 ± 0.22)     | 0.22 ± 0.22       |                 |
| Sum of fat fractions        | 0.26 ± 0.18       | 0.26 ± 0.20       | -0.00 ± 0.02    |

2 The mean difference is calculated as follow-up value minus baseline value.

3 Values are given in mean and SD; where data were not normally distributed median and range is given first.